Supplementary Figure 9 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 | AMiner
Supplementary Figure 9 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 9. hB6H12.3 induces stronger FcγRIIa-H131 activation than similar anti-CD47 based on the parent mB6H12 murine antibody, as assessed using a Jurkat NFAT reporter assay in the presence of WIL2-S target cells that express CD47.
原文链接
分享
引用
